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Type 1 diabetes is an autoimmune disease that manifests as impaired insulin secretion, with compounding
complications over time. Bhatt et al. (2015) investigate protective mechanisms in survivors of type 1 diabetes
by using induced pluripotent stem cells as geneticmodels, uncovering novel interactions betweenmicroRNA
and the DNA damage checkpoint pathway.Immune cell targeting of pancreatic b cells
is the putative cause of type 1 diabetes
(T1D), thought to be initiated by some
genetic predisposition or environmental
stress, then exacerbated by a positive
feedback loop driven by b cell apoptosis.
Antigens released during apoptosis will
recruit more immune cells, with the even-
tual result of total loss of functional b cells
(Bluestone et al., 2010). Dysregulation of
blood glucose secondary to loss of insulin
secretion is the primary physiological
consequence of T1D. Blood glucose
levels can be managed with insulin
replacement therapy, but often this treat-
ment is insufficient to avert cellular com-
plications induced by hyperglycemia.
Common sequelae of cellular complica-
tions in T1D include heart disease, limb
amputation, and blindness.
The unifying hypothesis concerning the
biochemical origin of cellular complica-
tions of T1D implicates the inhibition of
glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH) function by superoxide
accumulation as the causative mecha-
nism (Brownlee, 2001). Resultant shunt-
ing of various glycolytic intermediates to
alternative pathways in endothelial cells
induces apoptosis, leading to the compli-
cations associated with microvascular
damage such as diabetic neuropathy
and nephropathy. Rodent models of
T1D, while valuable, incompletely recapit-
ulate some cellular effects of chronic
blood glucose dysregulation (Calcutt
et al., 2009). Of particular relevance to
this study are the difficulties in studying
diabetic neuropathy and macrovascular
damage in rodent models of T1D, due to
fundamental physiological differences
between rodents and humans. To skirt
these difficulties, Bhatt et al. (2015)
employ induced pluripotent stem cell202 Cell Metabolism 22, August 4, 2015 ª201(iPSC) reprogramming from a carefully
selected cohort of T1D patients to study
the interplay of genetics and susceptibility
to the microvascular complications of
T1D.
Diseasemodeling with pluripotent stem
cells is a growing field, spurred on by the
advent of iPSC reprogramming technol-
ogy (Cherry and Daley, 2012). iPSCs
represent a means to direct testing of a
particular patient’s genotype in vitro in
any number of cell types, without immor-
talized cell lines or isolation of short-lived
primary cells from said patient. In the
study at hand, T1D patients who were
diagnosed more than fifty years ago
were segregated by clinical phenotype in
two groups (Figure 1), those with
microvascular complications (+C), and
those without microvascular complica-
tions (C). The experiment was designed
as a discovery effort, to transcriptionally
and proteomically profile primary fibro-
blasts and their cognate iPSCs with the
hopes of identifying some factor or
pathway differentially expressed in +C
patients that predisposed them to accu-
mulating microvascular damage.
The authors found that themiR200 fam-
ily is upregulated in both the fibroblasts as
well as the reprogrammed iPSCs from the
+C cohort. The ultimate conclusion from
this finding is that many of miR200’s tar-
gets are transcripts encoding DNA dam-
age checkpoint proteins. The authors
demonstrate that there is a concomitant
loss of accumulated DNA damage check-
point proteins in the +C cohort of fibro-
blasts and iPSCs, as well as an increase
in markers of cell death such as caspases
and pH2AX.
Rescue of the DNA damage checkpoint
pathway in the +C cohort of cells was
achieved by knockdown of miR200 via5 Elsevier Inc.siRNA. miR200 knockdown affected loss
of histone H2AX phosphorylation and
caspase-3 cleavage, suggesting that the
accrual of DNA damage in these primary
fibroblasts and reprogrammed iPSCs
was entirely a product of miR200-driven
suppression of the DNA damage check-
point pathways. This effect was also sus-
tained throughout neuronal differentiation
of the iPSCs. Neurons differentiated from
+C iPSCs accumulated pH2AX in the
nucleus, whereas C iPSCs did not.
Exogenous overexpression of miR200 in
differentiated neurons produced nuclear
pH2AX in cell lines derived from all clinical
backgrounds. These data strongly asso-
ciate miR200-mediated downregulation
of the DNA damage checkpoint proteins
with propensity for developing microvas-
cular complications of T1D.
The findings presented here are pro-
vocative for several reasons. For one,
miR200 is secreted in exosomes and is
detectable in serum, as observed here
and in other studies (Le et al., 2014). Le
et al. showed that exosome-packaged
miR200 derived from metastatic cancer
cells could prompt transdifferentiation
and metastasis in distal poorly metastatic
cancer cells. It is possible that miR200
upregulation in endothelia affected by
chronic hyperglycemia could be signaling
to other tissues via endocrine action of
miR200 in secreted exosomes. If this is
indeed the case, then exosome-mediated
miRNA signaling could be another mech-
anism for advancement of the symptoms
of microvascular and neuropathological
complications of T1D. It was recently
demonstrated that miR200 suppression
in b cells protects against cell death in a
model of type 2 diabetes, supporting the
Bhatt et al. (2015) study (Belgardt et al.,
2015).
Figure 1. Fibroblasts from T1D Patients with Microvascular Complications Exhibit
Decreased iPSC Reprogramming Efficiency Secondary to Upregulated miR200
(A) Bhatt et al. (2015) reprogrammed iPSCs from dermal fibroblasts taken from two groups of patients,
both with long-standing (50+ years) T1D. One group suffered microvascular complications (red), while
the other group did not (blue). Fibroblasts from the group with diabetic complications exhibited decreased
efficiencies both at the reprogramming stage and at the differentiation stage, where the researchers at-
tempted to derive neuronal and endothelial cells from the iPSCs.
(B) Transcriptome analyses revealed that cells obtained from the group of donors suffering frommicrovas-
cular complications of T1D expressed the miR200 family, concomitant with a decrease in expression of
target genes in the DNA damage checkpoint pathways and increased DNA damage accumulation.
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on transdifferentiation of cancer cells
(epithelial-mesenchymal transition, EMT)
has long been recognized (Korpal et al.,
2008), but this could be the first associa-
tion between miR200 expression and
reprogramming and differentiation effi-
ciencies of iPSCs. In the current publica-
tion, Bhatt et al. (2015) make note of a
disparity in iPSC reprogramming and dif-
ferentiation efficiency between their two
cohorts. Indeed, this disparity is what
prompted the transcriptomic studies of
the parental fibroblasts, leading to the ul-
timate finding of miR200 as a factor
related to DNA damage repair and
apoptosis in fibroblasts and differentiatedneurons from +C patients. The miR200
family exerts its control over EMT through
the ZEB transcription factors in cancer,
and perhaps it is playing some similar
role inhibiting reprogramming and differ-
entiation in this study.
Another point of emphasis to discuss in
the current study is the persistence of
miR200 differential expression in primary
fibroblasts, reprogrammed iPSCs, and
differentiated neuronal cells. This carry-
over of expression differentials must be
related to some underlying genetic or
epigenetic cause, but the authors have
yet to discover this mechanism. It is un-
derstood that certain epigenetic marks
can carry over during the reprogrammingCell Metabolism 2process, in a phenomenon referred to as
‘‘epigenetic memory’’ (Vaskova et al.,
2013). Careful analysis of whole-genome
sequencing and unbiased studies of
epigenetic marks could reveal themecha-
nism behind this robust gene expression
signature of the +C cohort.
Bhatt et al. (2015) have uncovered a
novel function of the miR200 family in
T1D. This may provide a link between
endothelial cell metabolism dysfunction
during chronic blood glucose dysregula-
tion and downstream effects on other
tissues.
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